Curevac's Covid-19 Vaccine Triggers Immune Response In Phase I Trial

by moneycontrol.com posted 7months ago 73 views
CureVac - backed by German biotech investor Dietmar Hopp, the Gates Foundation and GlaxoSmithKline - said volunteers developed a level of neutralising antibodies on par with people who had recovered from a serious case of COVID-19.

In this article